Key insights
- Barclays downgraded Travelers (TRV) to Underweight, citing concerns over EPS growth due to slowing premium growth, deteriorating margins in commercial lines, and potential faster erosion in personal lines. The firm forecasts flat EPS through 2028, contrasting with recent performance. Despite some positive analyst revisions, Barclays' bearish outlook on Travelers' ability to grow earnings and its capital flexibility suggests potential headwinds for the stock, implying a modest negative influence on the broader market if these concerns materialize.
Investing.com - Barclays downgraded Travelers Companies (NYSE:TRV) to Underweight from Equalweight on Friday and set a price target of $295. The stock currently trades at $303.90, above the analyst’s target, though InvestingPro data suggests the company remains undervalued with a Fair Value of $315.72.
The firm said the insurer will struggle to grow earnings per share over the next few years. Barclays forecast essentially flat EPS through 2028. This contrasts with the company’s recent performance, which delivered EPS of $33.62 over the last twelve months, trading at a P/E ratio of just 9.09—notably low for the insurance sector.
The analyst cited slowing premium growth, deterioration in commercial lines margins, and potential faster erosion of personal lines as key pressures. Share repurchases and favorable prior year development will not fully offset these headwinds, according to the firm.
Barclays said Travelers does not have the same capital flexibility as AIG, Chubb, or Arch for buybacks. The firm also noted that Travelers’ reserves do not appear as redundant as they were in the 2014-2016 soft-market period, particularly given social inflation trends that have pressured casualty loss picks.
The $295 price target implies a 3% downside over the next 12 months, Barclays said.
In other recent news, Travelers Companies Inc. has reported several significant developments. Roth/MKM raised its price target for Travelers to $345, maintaining a Buy rating, following the company’s first-quarter 2025 results that showed core income of $7.71 per share, surpassing both the consensus estimate of $7.03 and Roth/MKM’s estimate of $7.43. Meanwhile, BMO Capital Markets also increased its price target to $314 from $297, keeping an Outperform rating, and noted that it expects Travelers’ earnings per share to exceed consensus estimates in the coming years. Additionally, JPMorgan upgraded Travelers’ stock rating to Neutral from Underweight, adjusting its price target to $322 due to improved earnings estimates for 2026 and 2027.
Travelers has also entered into a new $1.2 billion five-year revolving credit agreement, replacing its previous $1.0 billion facility. This agreement involves Citibank, BofA Securities, and JPMorgan Chase as key financial partners. BMO Capital reaffirmed its Outperform rating on Travelers, expressing a positive outlook despite anticipated pricing deceleration in the commercial insurance market. These recent developments highlight the financial community’s confidence in Travelers’ future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.